Strata Partners is delighted to announce that it arranged and acted as exclusive corporate finance adviser to Limerston Capital in relation to their recent acquisition of the microbiology and in-vitro toxicology testing activities of Gosport, UK-based Wickham Laboratories to form a new, standalone business, Wickham Micro.
As part of the acquisition, a separate entity for the in-vivo toxicity testing part of the business has been created and will remain under the control of the previous owners. Wickham Micro has provided expert microbiology and in-vitro toxicology services to the pharmaceutical and medical device sectors for almost 60 years. The team works with global brands to deliver a comprehensive range of testing services for the safe and efficient release of their products.
The new business will be led by pharma services industry veteran Mark Hammond, who was introduced to Limerston Capital and the Wickham Micro acquisition opportunity by Strata. With strong fundamentals, an impressive client list and a long-standing reputation for excellence and quality, Wickham Micro offers a platform for significant growth, both organic and inorganic.